Plant phosphoglucose isomerase genes lack introns and are expressed in Escherichia coli

Nuclear genes that appear to encode both cytosolic and plastid isozymes of phosphoglucose isomerase (PGI), an essential glycolytic enzyme, have been isolated from three diploid species of the annual wild flower genus Clarkia (Onagraceae). The genes do not contain introns and are expressed to varying degrees in Escherichia coli when cloned in either Charon 35 phage or pUC plasmid vectors. The PGI proteins synthesized in E. coli form dimers, are catalytically active, and their electrophoretic mobilities are similar to those of appropriate Clarkia PGIs. The nucleotide sequence of a gene encoding a plastid isozyme of C. unguiculata is described.     

Alloreactivity of an OVA-specific T-cell clone

A T-cell clone (Lyl-03) derived from BALB/cBy mice, though highly specific for OVA/A^d, reacted to allogeneic spleen cells of 6 of 12 H-2 haplotypes tested. The reactivity to each particular H-2 haplotype required the expression of a non-major histocompatibility complex (MHC) gene product present on the B cells of certain strains of mice. All the alloreactive responses were MHC restricted and were inhibited by class II-specific and L3T4-specific monoclonal antibodies. The non-MHC gene product, X, is a new lymphocyte-stimulating determinant that is not expressed in mice with the xid defect. We favor a model that proposes two independent sites (or receptors) for X and the class II molecule. Contrary to previous models for alloreactivity, the anti-MHC site is not directed to a polymorphic receptor for self-class II epitope on the foreign class II molecule, but rather to a conserved determinant present on both self- and allo-class II molecules. If there is only one antigen receptor on the T-cell clone Lyl-03, then anti-X receptor must bind to a cross-reactive determinant found on immunogenic OVA and the non-MHC coded gene product expressed on the cell surface membrane. We further postulate that class II plus X recognition may be a general rule for alloreactive as well as autoreactive responses. Thus, both allo-class II and allo-class I reactive T cells are similar in that both bind a non-MHC coded gene product prior to activation.Abbreviations used in this paper: APC antigen-presenting cell(s) - Con A concanavalin A - Cl. clone - DME Dulbecco's modified Eagle's medium - FCS fetal calf serum - H-2 histocompatibility-2 - MHC major histocompatibility complex - MLR mixed lymphocyte response - Mls mixed lymphocyte stimulating - OVA chicken ovalbumin - X unknown cell-surface antigen - xid immunodeficiency mapped to the X chromosome     

Radiation damage repair capacity of a human germ-cell tumour cell line: inhibition by 3-aminobenzamide

The capacity of a human germ-cell tumour line to repair radiation damage has been investigated by means of a clonogenic assay. Dose-rate dependence studies, split-dose experiments and experiments designed to measure repair of potentially lethal damage have been performed. The cells showed some ability to repair radiation-induced damage in all three types of experiment. An attempt has been made to understand the possible cellular mechanisms of these repair processes by the use of 3-aminobenzamide (3-AB), an agent thought to act by inhibition of ADP-ribosylation. 3-AB added 2 h prior to and removed 18 h after irradiation at a non-toxic dose to unirradiated cells caused a small but consistent increase in cell kill with acute (150 cGy min-1) irradiation, largely involving a reduction in the shoulder region of the survival curve, but had a greater effect in increasing cell kill at a dose rate of 7.6 cGy min-1 and an even greater effect at a dose rate of 1.6 cGy min-1. When 3-Ab was present 2 h prior to the first dose and between two equal doses in a split-dose experiment, inhibition of split-dose recovery was observed. In addition, some inhibition of potentially lethal damage recovery was observed with 3-AB. A possible role for poly(ADP-ribosylation) is thus implicated in the repair of radiation-induced damage of this human tumour cell line during continuous low dose rate or fractionated radiation schedules, although other effects of 3-AB on respiratory metabolism and/or purine synthesis cannot be eliminated as the cause of the observed inhibitory effects.     

Arachidonic acid and linoleic acid supplementation increase prostanoid production in rats fed a butter-enriched diet

Male Sprague Dawley rats were fed a butter-enriched diet (50% fat) for 2 weeks and then supplemented orally with either 90 mg of ethyl arachidonate or ethyl linoleate daily for 2 weeks. For comparative reasons, one group of animals was fed standard laboratory rat chow for 4 weeks. Aortic prostacyclin (PGI2) production, platelet aggregation and thromboxane A2 (TXA2) production and plasma and aortic phospholipid (PL) fatty acids were measured. When compared to butter-fed rats, aortic PGI2 production, collagen-induced platelet aggregation and TXA2 production were significantly increased in rats supplemented with ethyl arachidonate to levels similar to those seen in chow-fed rats. Ethyl linoleate supplementation also tended to increase aortic PGI2 production, collagen-induced platelet aggregation and TXA2, but not to the same extent. These changes were accompanied by increases in the level of arachidonic acid and linoleic acid in aortic and plasma PL and a decrease in the level of eicosapentaenoic acid (EPA) and docsahexaenoic acid (DHA). These data indicate that supplementation with small doses of preformed arachidonic acid was more effective than supplementation with its precursor, linoleic acid, in reversing the effects on prostanoid production and phospholipid fatty acid composition in rats fed diets enriched with butter.     

Protection of mice against mixed fission neutron-gamma (n: gamma = 1:1) irradiation by WR-2721, 16,16-dimethyl PGE2, and the combination of both agents

The survival of mice after whole-body exposure to a modified fission neutron-gamma field (n: gamma = 1:1) was used to examine radiation protection by WR-2721, 16,16-dimethyl PGE2(DiPGE2), and the combination of both agents. Administration of WR-2721 (453 mg/kg) increased the LD50/30 from 5.24 to 7.17 Gy (DMF = 1.37), whereas pretreatment with DiPGE2 (1.6 mg/kg) increased the LD50/30 to 5.77 Gy (dose modification factor (DMF) = 1.10). The combination of 453 mg/kg WR-2721 and 0.4 mg/kg DiPGE2 resulted in an LD50/30 of 7.33 Gy, yielding a DMF of 1.39. However, no significant difference in protection was obtained with the combination of the two agents compared to that seen with WR-2721 alone.